Key result
In patients with c-mpl+ AML, significant TPO-associated blast cell proliferation or decreased apoptosis was observed and highly correlated with low in vivo TPO levels (P < .001).
Population
99 patients with acute lymphoblastic leukemia (ALL, n=60) or acute myeloblastic leukemia (AML, n=39)
Comparison
Measurement of serum TPO levels and in vitro… vs Patients with ALL vs. c-mpl-deficient AML vs…
Design
Cohort
Authors
Loading...
Nonfunctional c-mpl on ALL blasts may impair TPO responsiveness; leaves open its impact on leukemic proliferation or therapy.
Observational (n=99)
p-value: p=< .001
In patients with AML, inadequate TPO levels are secondary to TPO clearing by functional c-mpl receptor myeloid blast cells, suggesting TPO acts as an in vivo myeloid leukemic growth factor.
Corazza et al. (2005) conducted an observational in Acute lymphoblastic leukemia (ALL) or acute myeloblastic leukemia (AML) (n=99). Functional c-mpl receptor (c-mpl+) vs. c-mpl-deficient (c-mpl-) AML or ALL was evaluated on In vitro significant TPO-associated blast cell proliferation or decreased apoptosis correlation with low in vivo TPO levels (p=< .001). In patients with c-mpl+ AML, significant TPO-associated blast cell proliferation or decreased apoptosis was observed and highly correlated with low in vivo TPO levels (P < .001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: